Through the HELM Cluster, the emirate has brought together research institutions, advanced healthcare infrastructure, genomics programs, manufacturing capabilities, and distribution networks within a single ecosystem.
In Japan alone, 21,000 new cases and 7,000 deaths were reported that year, with metastatic renal cell carcinoma (RCC) accounting for approximately 85% of all kidney cancers.
For MSD, this acquisition is part of a broader strategy to diversify its pipeline before its blockbuster immunotherapy Keytruda loses patent protection.